{"id":9202,"date":"2024-02-01T10:37:00","date_gmt":"2024-02-01T02:37:00","guid":{"rendered":"https:\/\/flcube.com\/?p=9202"},"modified":"2024-10-24T10:46:57","modified_gmt":"2024-10-24T02:46:57","slug":"manhattan-biosolutions-strikes-agreement-with-biocytogen-for-access-to-novel-tumor-antigens","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=9202","title":{"rendered":"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens"},"content":{"rendered":"\n

Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315<\/a>), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is notably overexpressed in multiple solid tumor types, including those that are treatment-resistant, aggressive, and metastatic.<\/p>\n\n\n\n

The antigen in question is an ovarian-specific developmental signaling protein typically found in ovary, testis, and adrenal tissues, but it is overexpressed in various cancers such as ovarian, endometrial, cervical, renal, hepatic, colorectal, and lung tumors. The agreement grants Manhattan BioSolutions access to a diverse panel of lead fully-human monoclonal antibodies generated through Biocytogen\u2019s cutting-edge RenMab and RenLite platforms.<\/p>\n\n\n\n

Manhattan BioSolutions will conduct a thorough evaluation of these antibodies, assessing binding affinity, internalization, species cross-reactivity, and other developability parameters in cellular and biochemical assays. This evaluation aims to determine the suitability of these antibodies for integration into antibody-based therapeutic modalities that carry Manhattan BioSolutions\u2019 proprietary RNA targeting payloads. The most promising candidates identified through this process may be selected for further development into precision medicines, potentially offering new treatment options for chemoresistant, aggressive, or metastatic tumors.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,16,1214,1566],"class_list":["post-9202","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-cancer","tag-hkg-2315","tag-manhattan-biosolutions"],"yoast_head":"\nManhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is notably overexpressed in multiple solid tumor types, including those that are treatment-resistant, aggressive, and metastatic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=9202\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=9202\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-01T02:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T02:46:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9202#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9202\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens\",\"datePublished\":\"2024-02-01T02:37:00+00:00\",\"dateModified\":\"2024-10-24T02:46:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9202\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Cancer\",\"HKG: 2315\",\"Manhattan BioSolutions\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9202#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9202\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=9202\",\"name\":\"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-02-01T02:37:00+00:00\",\"dateModified\":\"2024-10-24T02:46:57+00:00\",\"description\":\"Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is notably overexpressed in multiple solid tumor types, including those that are treatment-resistant, aggressive, and metastatic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9202#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9202\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9202#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens - Insight, China's Pharmaceutical Industry","description":"Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is notably overexpressed in multiple solid tumor types, including those that are treatment-resistant, aggressive, and metastatic.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=9202","og_locale":"en_US","og_type":"article","og_title":"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=9202","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-02-01T02:37:00+00:00","article_modified_time":"2024-10-24T02:46:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=9202#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=9202"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens","datePublished":"2024-02-01T02:37:00+00:00","dateModified":"2024-10-24T02:46:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=9202"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Cancer","HKG: 2315","Manhattan BioSolutions"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=9202#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=9202","url":"https:\/\/flcube.com\/?p=9202","name":"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-02-01T02:37:00+00:00","dateModified":"2024-10-24T02:46:57+00:00","description":"Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is notably overexpressed in multiple solid tumor types, including those that are treatment-resistant, aggressive, and metastatic.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=9202#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=9202"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=9202#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9202"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9202\/revisions"}],"predecessor-version":[{"id":9203,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9202\/revisions\/9203"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}